Johnson & Johnson pays $175M, commits to $1.6B in milestones for Arrowhead hepatitis B drug

Johnson & Johnson has paid $175 million upfront for the global rights to Arrowhead’s phase 1/2 RNAi hepatitis B drug. The outlay, plus $1.6 billion in milestones, has bought J&J a drug that slashed levels of hepatitis B virus in a small, early-phase assessment.